ash 2018: dara velcade dex with or without venetoclax
Published 5 years ago • 128 plays • Length 2:27Download video MP4
Download video MP3
Similar videos
-
1:38
ash 2018: dara/rev/dex/velcade for newly diagnosed multiple myeloma patients
-
6:12
ash 2018: using daratumumab early with standard myeloma combos for newly diagnosed patients
-
7:31
clinical trial: darzalex (daratumamab) with revlimid/velcade/dex for newly diagnosed myeloma
-
8:26
ash 2018: selinexor, daratumumab and dexamethasone for relapsed/refractory myeloma
-
2:09
ash 2018: deter - dara rev dex for high-risk smoldering myeloma
-
42:41
phase i study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib...
-
2:48
bellini, a phase iii study of venetoclax or placebo in combination with bortezomib and dex in rrmm
-
16:11
all about velcade (bortezomib) for myeloma patients
-
1:34
ash 2018: isatuximab in relapsed or refractory multiple myeloma
-
6:14
results of iberdomide in combination with dex and daratumumab or bortezomib in patients with rrmm
-
14:28
all about darzalex (daratumumab)
-
3:45
ash 2018: fighting myeloma resistance with personalized 3d tumor modeling
-
2:10
new developments at ash | rafat abonour, md | ash 2022
-
2:12
myeloma australia ceo, steve roach, speaks about darzalex
-
13:40
venetoclax for myeloma | therapies on the horizon
-
2:36
efficacy and safety of daratumumab, bortezomib, and dex (d-vd) vs vd in first relapse patients
-
3:52
is dara being used in the frontline setting for myeloma patients?